Related Experiment Video
Updated: Jun 20, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Imatinib in gastrointestinal stromal tumor: does treatment duration matter?
Antoine Adenis1, Nicolas Penel, Jean-Yves Blay
1Department of Medical Oncology, Centre Oscar Lambret, Lille, France. a-adenis@o-lambret.fr
Abstract:
Whereas 10 years ago no effective systemic therapy was available for gastrointestinal stromal tumors, the introduction of imatinib into clinical practice has dramatically improved the outcome of advanced disease, through favorable impact on disease-free survival for some patients with a localized and resectable tumor. This review provides a clinical perspective on the available data, evidence- or expert-based, for calculating the optimal treatment duration with imatinib.
Related Concept Videos
Drugs that Stabilize Microtubules
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
